Sort   by:  
 Page size 
UnknownsST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial.
Not available
S-EPMC12022249 | biostudies-literature
UnknownFinal results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.
Not available
S-EPMC9132543 | biostudies-literature
UnknownCardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.
Not available
S-EPMC11327784 | biostudies-literature
UnknownRemdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Not available
S-EPMC8439621 | biostudies-literature
UnknownRepurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
Not available
S-EPMC7727327 | biostudies-literature
UnknownRegional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis.
Not available
S-EPMC10878545 | biostudies-literature
UnknownCost-Utility Analysis of Accelerated and Standard Strategies for Renal Replacement Therapy Initiation.
Not available
S-EPMC12495491 | biostudies-literature
UnknownA Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial.
Not available
S-EPMC9404618 | biostudies-literature
UnknownFactors associated with adverse haemodynamic events during the STARRT-AKI trial: a post-hoc secondary analysis.
Not available
S-EPMC12751851 | biostudies-literature
UnknownLack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection.
Not available
S-EPMC11215417 | biostudies-literature
Sort   by:  
 Page size